Microba Life Sciences Limited (ASX:MAP)
Australia · Delayed Price · Currency is AUD 0.0870
+0.0010 (1.16%)
At close: Feb 4, 2026
Microba Life Sciences Revenue
In the fiscal year ending June 30, 2025, Microba Life Sciences had annual revenue of 15.67M AUD with 29.60% growth. Microba Life Sciences had revenue of 7.58M in the half year ending June 30, 2025, with 132.05% growth.
Revenue
15.67M
Revenue Growth
+29.60%
P/S Ratio
3.38
Revenue / Employee
n/a
Employees
n/a
Market Cap
52.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 15.67M | 3.58M | 29.60% |
| Jun 30, 2024 | 12.09M | 6.67M | 123.06% |
| Jun 30, 2023 | 5.42M | 731.49K | 15.60% |
| Jun 30, 2022 | 4.69M | 956.20K | 25.62% |
| Jun 30, 2021 | 3.73M | 823.42K | 28.31% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Healius | 1.34B |
| Australian Clinical Labs | 741.27M |
| Integral Diagnostics | 627.22M |
| Monash IVF Group | 271.92M |
| Genetic Signatures | 19.75M |
| Cryosite | 14.12M |
| Genetic Technologies | 9.17M |
| Rhythm Biosciences | 3.19M |